Breast tumours from BRCA1 and BRCA2 mutation carriers are genetically instable and display speci®c patterns of chromosomal aberrations, suggestive of distinct genetic pathways in tumour progression. The frequency of abnormalities aecting chromosome 17p and the TP53 gene was determined in 27 breast tumours from 26 female patients carrying the Icelandic BRCA2 founder mutation (999del5). Loss of heterozygosity (LOH) was detected in 23 of the 27 tumours (85%). The majority of tumours manifesting LOH had lost a large region on 17p, although a more restricted loss, including the TP53 locus was seen in a few tumours. Positive p53 immunostaining was observed in 18 of 26 tumours (69%). However, mutations in the TP53 gene were detected in only three tumours (11%), including a missense (codon 139) and a nonsense mutation (codon 306) in two tumours with moderate p53 expression and a frameshift deletion (codon 182) in a tumour with no detectable p53 expression. Positive p53 immunostaining, mainly weak, was observed in 16 of the 24 tumours (66%) without TP53 mutation. The high frequency of LOH at chromosome 17p13 suggests that one or more genes from this region are involved in the development of BRCA2-induced breast cancer. The frequent ®nding of weak overexpression of, presumably wild type p53 protein, suggests an alternative mechanism of TP53 involvement speci®c to these tumours.
Introduction
Breast cancer is one of the most common malignancies in women living in the Western countries. About 5 ± 10% of the cases are believed to be due to germline mutations in breast cancer susceptibility genes (Newman et al., 1988; Lynch et al., 1990) . In the majority of the families with multiple cases of breast cancer the disease has been shown to be due to mutations in either of the two tumour suppressor genes BRCA1 and BRCA2 (Easton et al., 1993; Wooster et al., 1994) . Since mutations in the BRCA1 and BRCA2 genes are rarely found in sporadic tumours (Futreal et al., 1994; Teng et al., 1996) the question arises whether the progression pathway of carcinogenesis may be dierent in breast tumours in genetically predisposed individuals and sporadic cases. A recent study using comparative genomic hybridization (CGH) to evaluate genomic changes in tumours from BRCA1 and BRCA2 carriers showed a high incidence of genetic abnormalities in these tumours (Tirkkonen et al., 1997) . The tumours from BRCA2 carriers showed a high frequency of aberrations at many of the same chromosome regions shown to be involved during sporadic tumour development such as 13q, 1p, 3p, 6q, 8p, 11q, 17q22-q24, 17p, 18q and 20q13 but lower frequency at chromosomes such as 7q and 16q. Chromosome 17p harbours the p53 gene. TP53 is considered to be a tumour suppressor gene exerting growth-regulatory functions in response to DNA damage by directly inhibiting DNA replication (Soddu et al., 1996; Cox et al., 1995) or inducing apoptosis (White, 1996; Levine 1997) . Mutations in the TP53 gene are among the most common genetic alterations observed in human neoplasia (Hollstein et al., 1991) and often result in the accumulation of a nonfunctional protein (Iggo et al., 1990; Kastan et al., 1991; Levine et al., 1991) . TP53 mutations have been reported in sporadic breast cancer and are in general associated with adverse prognosis (Saitoh et al., 1994; Bergh et al., 1995) . In this paper genomic changes occurring at chromosome 17p in tumours from BRCA2 carriers were studied. We used microsatellite markers to map loss of heterozygosity, and we evaluated the involvement of the TP53 gene in the tumour progression by mutational analysis of the gene and immunohistochemical staining of the p53 protein. We also analysed the samples for LOH at chromosome 13q12-q14, harbouring the BRCA2 gene, and at chromosome 7q21-q35 which according to the CGH results is rarely deleted in BRCA2 tumours (Tirkkonen et al., 1997) .
Results
Twenty-seven tumours from female breast cancer cases with the 999del5 BRCA2 mutation were analysed. Summarised in Table 1 are the results of the LOH mapping with ten markers at 17p, the p53 immunohistochemical staining and the mutational analysis of the TP53 gene. Clinico-pathological information is also included, and data from the LOH analysis at chromosomes 13q12-q14 and 7q21-q35 based on six and nine markers, respectively. The two metastatic tumours analysed (121ii and 123ii) showed the same LOH and mutation pattern as the primary tumour (see Table 1 ).
LOH analysis
We detected LOH at 17p13 with at least one marker in 23 of the 27 tumours analysed (85%). Twenty-one tumours showed LOH at the TP53 locus. In one tumour (no. 124) LOH was detected at a region telomeric to TP53, but not at the TP53 locus itself (Figure 1a) . In sample 123i LOH was detected at the TP53 locus and not at other informative markers at 17p (Figure 1b) .
Fifteen samples were analysed with markers at 7q21-q35 and LOH at one or more markers was detected in four tumours (27%). All but two of 23 samples analysed showed LOH at the BRCA2 locus (91%).
Staining and mutational analysis of p53
Positive staining of the p53 protein was seen in 18 of the 26 tumour samples (69%) available for analysis, including one case (no. 126) diagnosed with in situ Gyapay et al. (1994) are shown in centimorgans (cM). a: bilateral case; ii: metastatic tumour from i; ND: not determined; ER: estrogen receptor content: +=510 fmol/mg protein, 7=510 fmol/mg protein; PgR: progesterone receptor content: +=525 fmol/mg protein, 7=525 fmol/mg protein; Node status: +=positive, 7=negative; grade: *lobular cancer; **in situ cancer; Sphase: +=57%, 7=57%; Ploidy: +=aneuploid, 7=diploid; immunostaining: 7=negative, sca=scattered, +=weak, ++=moderate; LOH at 7q or 13q: +=loss of heterozygosity at one or more markers tested, 7=retention of heterozygosity at all informative markers cancer. In 12 cases with positive staining where both in situ and invasive tumour growth was seen, staining was detected in cells of both components (Figure 2 ). Four of the ®ve tumours that did not show LOH at the TP53 locus stained positively for the p53 protein (Table 1) . We used SSCP to look for TP53 mutations and were able to identify band shifts in only four of the tumours. A nucleotide deletion at codon 182 (TGC to GC), which leads to a frameshift mutation and a premature translation termination (246ter), was identi®ed in one of the negatively staining tumours (no. 121i), and the same mutation was detected in the metastatic growth from this tumour (121ii). A missense mutation at codon 139 (Lys to Asn) and a nonsense mutation at codon 306 (Arg to Stop) were observed in two tumours (nos. 111 and 112) with positive immunostaining. The remaining SSCP-band shift, observed in a tumour without detectable staining, was found to be due to a known polymorphism at codon 213 (CGA to CGG). The same mutations have previously been detected in studies of tumours from sporadic breast cancer cases and are listed in the Human Gene Mutation Database (Cardi, UWCM; http: //www.cf.ac.uk/ UWCM/mg/hgmdO.html).
Discussion
We have recently reported a high frequency of genomic alterations, as seen by CGH analysis, in breast tumours from both BRCA1 and BRCA2 mutation carriers (Tirkkonen et al., 1997) . The CGH results clearly suggested that the accumulation of somatic genetic changes is not random and some chromosome regions are aected more frequently than others. The LOH results presented in this paper support the CGH data, where the involvement of 7q is seen in 27% of the tumours analysed versus 85% and 91% at 17p and 13q respectively. The LOH mapping results indicated the TP53 gene as a possible target of the allelic deletions. This is supported by the high number of tumours positively staining for the p53 protein, taking into consideration the known relationship between gene mutation and protein accumulation (Iggo et al., 1990; Kastan et al., 1991; Levine et al., 1991) . However, TP53 mutations were detected in only 11% of the tumours, suggesting the involvement of alternative mechanisms that give rise to (mainly weak), overexpression of wildtype p53. For instance, the p53 protein is known to be modi®ed and stabilised by phosphorylation in response to DNA damage and the action of DNA damage sensor proteins (Kastan et al., 1992; Levine, 1997) . One cannot exclude the possibility that the deletions are targeted to another gene on 17p as the majority of tumours manifesting LOH had lost a large region including the TP53 gene as well as markers centromeric and, most often, telomeric to TP53. In two cases (see 122, 123i and 123ii in Table 1 ) the deletion pattern was in accordance with the speci®c loss of TP53 or a closely located gene, while in one tumour (no. 124) LOH was detected both telomeric and centromeric to TP53 but not at the TP53 locus itself. The existence of a tumour suppressor gene telomeric to TP53 has been suggested previously (Merlo et al., 1994; Cornelis et al., 1994) and cannot be excluded as a target gene in these tumours. It should be emphasised that in this study any positive staining was judged to be signi®cant and the staining in all but one of these tumours was weak. According to previously published studies disparity is frequently encountered when correlating immunohistochemical ®ndings with DNA mutations of the TP53 gene (Jacquemier et al., 1994; Yandell and Thor, 1993) , especially regarding samples with weak staining (Gretarsdottir et al., 1996; Hall and Lane, 1994) . Possible explanations for the positive staining of p53 in the 16 cases where no TP53 mutations were detected are that the protein expression was caused by mutations in another gene that prolongs the half-life of the p53 protein, by mutations that were not detected by SSCP due to co-migration of wild-type and mutant alleles, by mutations in exons other than those screened in this study by SSCP or by mutations that were not detected due to a dilution factor of normal cells. The two last explanations are not very likely since relatively few mutations of the TP53 gene have been found to occur outside the exons tested in this study (Saitoh et al., 1994; SjoÈ gren et al., 1996) and contamination of the tumours by normal cells is not large as LOH was detected in 91% of the samples.
The high frequency of positive staining of p53 in the tumours of BRCA2 carriers determined here is comparable to what has been reported earlier for BRCA1 tumours Sobol et al., 1997) and higher than reported in similar studies on sporadic breast cancer (Gretarsdottir et al., 1996; Cornelis et al., 1994; Runnebaum et al., 1991) . In agreement with results of histopathological studies showing BRCA2 tumours to be of signi®cantly higher grade than sporadic tumours (Marcus et al., 1996; Lakhani et al., 1997) , most of the tumours in this study are grade II and III. A signi®cant association between p53 abnormalities and higher histological grade has been shown in sporadic tumours (Gretarsdottir et al., 1996; Umekita et al., 1994; Bhargava et al., 1994) . In this study no association was seen between p53 aberrations and histological grade or the other recognised prognostic factors listed in Table 1 . In 12 cases where both in situ and invasive tumour growth was seen, staining was detected in cells of both components. Staining was also seen in the tumour cells of one case (no. 126) diagnosed with in situ cancer.
The interaction recently suggested between the BRCA proteins and Rad51 protein in meiotic and mitotic recombination and DNA repair (Scully et al., 1997; Sharan et al., 1997) , is in accordance with a role of BRCA2 and BRCA1 in preservation of genome integrity. Thus, cells without BRCA1 or BRCA2 activity might be defective in the repair of lesions such as DNA double-strand breaks (Scully et al., 1997; Sharan et al., 1997) . In order to tolerate and survive with such DNA damage, cells must also acquire a deregulation in growth arrest and apoptosis. The results of the present study indicate that at an early stage in the development of BRCA2 predisposed tumours the p53 pathway is activated, and at some point either bypassed or inactivated by an unknown mechanism.
Materials and methods

Patients and tumour material
Screening of 459 randomly chosen breast cancer cases diagnosed in the years 1989 ± 1994 revealed 39 female patients with the 999del5 BRCA2 mutation (Johannesdottir et al., 1996) . Paired blood and tumour DNA were available from 27 primary breast tumours from 26 females (one bilateral case). These tumours were removed from the patients prior to any treatment. Two metastatic tumours were also available from 999del5 BRCA2 mutation carriers. Conventional methods were used for DNA extraction from blood and tumour material. The samples were subjected to PCR analysis using DynaZyme TM polymerase (Finnzymes Oy, Espoo, Finland) in the buer solution provided by the manufacturer. The TP53.15 marker, described by Jones and Nakamura (1992) and mapping within the TP53 gene, was obtained from Pharmacia Biotech (Denmark). All the other markers were obtained from Research Genetics (Huntsville, AL); D17S926, D17S796, D17S945, D17S947, D17S921, D17S953, D17S925, D17S798, D17S933, D13S283, D13S1246, D13S260, D13S171, D13S267, D13S263, D7S492, D7S518, D7S515, D7S501, D7S523, D7S471, D7S522, D7S480, D7S500. PCR products were subjected to 6.5% acrylamide denaturing gels and detected by the method of Vignal et al. (1993) . Autoradiograms were inspected visually by three independent viewers, comparing the intensity of alleles from normal and tumour DNA. Any absence or signi®cant decrease of one allele relative to the other was considered loss of heterozygosity (LOH). Relevant information regarding pathological factors of the tumours was recorded by pathologists at our department. Tumour grade was assessed by a modi®ed BloomRichardson system (Elston, 1987) . Estrogen-and progesterone-receptors (ER and PgR) were analysed using a ligand binding assay. S-phase fraction and DNA-ploidy were analysed using a FACScan¯ow cytometer (BectonDickinson) utilising paran embedded tissue. The Fisher's exact test (Abacus Concepts, Survival Tools for StatView, Berkeley, CA) was used to assess the relationship between p53 staining and/or TP53 mutations and clinico-pathological factors.
Mutation and sequencing analysis
The PCR ampli®cation and SSCP conditions for exons 5 ± 9 are described by El-Naggar et al. (1995) , and for exon 4 by Deng et al. (1994) . PCR products were diluted 1 : 4 in 95% formamide, 10 mM NaOH, 0.025% xylene cyanol and 0.025% bromophenol blue and denatured at 958C for 8 ± 10 min. The mixture was applied to 0.56MDE (Mutation Detection Enhancement, AT Biochem, no 1-500-01), 0.66TBE gels with or without 5 or 10% glycerol. The gels without glycerol and the 5% glycerol gels were run at 30 W for 6 ± 10 h at room temperature; the 10% glycerol gels were run at 48C for 4 h. The PCR products were detected with the same non-radioactive method as used for the microsatellite markers mentioned above. Samples positive in the SSCP analysis were subjected to a new PCR reaction with a biotinylated reverse primer and solid phase sequencing was carried out. The PCR products were immobilized on streptavadin beads (M-280; Dynal) and denatured with alkaline. The single-stranded biotinylated DNA template was sequenced using Sequenase 2.0 and [a-33 P]dATP (Amersham, Buckinghamshire, England).
Immunohistochemistry
Immunohistochemical staining of the p53 protein was performed with a commercially available antibody (clone Chromosome 17p13 and tumour development in BRCA2 mutations carriers G Eiriksdottir et al D07, Novocastra Laboratories, Newcastle upon Tyne, UK) utilizing formalin ®xed 4m paran sections. This antibody recognizes both mutant and wild type p53. Sections were pretreated in an 850 watt microwave oven in citrate buer at pH 6.0 for 265 min at full power. The sections were incubated with the primary antibody for 30 min at a 1 : 50 dilution and subsequently incubated with a second goat anti-mouse biotinylated antibody (Dako, Glostrup, Denmark) for 30 min before being reacted with a streptavadinbiotin-peroxidase complex (Dako) for 30 min (DAKO, Glostrup, Denmark). Diaminobenzidine tetrahydrochloride was used as chromogen to detect the peroxidase activity.
Results were scored according to the method of Fisher et al. (1994) . In brief, strong staining is classi®ed as dark nuclear staining in 450% of cells; moderate staining is dark staining in 550% of cells or moderate staining in 450% of cells; and weak staining is moderate staining in 550% of cells or pale staining in any proportion of cells.
Scattered staining is dark nuclear staining in widely scattered cells.
